Economic Impact of Respiratory Syncytial Virus Infections in Children Under 5 Years of Age Attending Primary Care in Italy: A Prospective Cohort Study in Two Regions
Costs associated with RSV infections in young children in primary care are considerable due to a substantial number of paediatrician visits and high rates of parental work absence. These costs are important to include in decision-making regarding the implementation of new RSV immunization strategies in national immunization programmes.
Authors
- Elisabetta Pandolfi (ORCID: https://orcid.org/0000-0003-2424-2736)
- Fasika Molla Abreha
- Jojanneke van Summeren (ORCID: https://orcid.org/0000-0002-2835-6995)
- Rolf Kramer (ORCID: https://orcid.org/0000-0002-6095-4338)
- Caterina Rizzo (ORCID: https://orcid.org/0000-0002-5583-7508)
- Daniela Loconsole (ORCID: https://orcid.org/0000-0003-2057-9745)
- W J Paget (ORCID: https://orcid.org/0000-0002-1503-2481)
- Maria Chironna (ORCID: https://orcid.org/0000-0002-1043-1256)
- Valérie D. V. Sankatsing
Institutions
- University of Pisa (IT)
- Sanofi (France) (FR)
- Netherlands Institute for Health Services Research (NL)
- Ono Pharmaceutical (Japan) (JP)
- Bambino Gesù Children's Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/irv.70074
- Citations
- 2
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- AstraZeneca
- Sanofi
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Seqirus
- Rijksinstituut voor Volksgezondheid en Milieu